Toyota|$17.87 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.03 (¥3,960)+0.00%▲ (in JPY terms)
SoftBank|$28.78 (¥4,554)-6.01%▼ (in JPY terms)
MUFG|$21.18 (¥3,351)-3.65%▼ (in JPY terms)
Keyence|$511.37 (¥80,910)-0.61%▼ (in JPY terms)
Nintendo|$54.86 (¥8,680)+1.63%▲ (in JPY terms)
NTT|$1.12 (¥177)+1.14%▲ (in JPY terms)
Takeda|$39.88 (¥6,310)+1.06%▲ (in JPY terms)
Tokyo Electron|$63.74 (¥10,085)-2.56%▼ (in JPY terms)
Recruit|$118.82 (¥18,800)+0.13%▲ (in JPY terms)
ITOCHU|$14.52 (¥2,298)-0.95%▼ (in JPY terms)
Honda|$11.40 (¥1,804)-0.19%▼ (in JPY terms)
Shin-Etsu|$37.09 (¥5,869)-1.63%▼ (in JPY terms)
Tokio Marine|$3.44 (¥544)-1.91%▼ (in JPY terms)
Fast Retailing|$476.29 (¥75,360)+2.04%▲ (in JPY terms)
Toyota|$17.87 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.03 (¥3,960)+0.00%▲ (in JPY terms)
SoftBank|$28.78 (¥4,554)-6.01%▼ (in JPY terms)
MUFG|$21.18 (¥3,351)-3.65%▼ (in JPY terms)
Keyence|$511.37 (¥80,910)-0.61%▼ (in JPY terms)
Nintendo|$54.86 (¥8,680)+1.63%▲ (in JPY terms)
NTT|$1.12 (¥177)+1.14%▲ (in JPY terms)
Takeda|$39.88 (¥6,310)+1.06%▲ (in JPY terms)
Tokyo Electron|$63.74 (¥10,085)-2.56%▼ (in JPY terms)
Recruit|$118.82 (¥18,800)+0.13%▲ (in JPY terms)
ITOCHU|$14.52 (¥2,298)-0.95%▼ (in JPY terms)
Honda|$11.40 (¥1,804)-0.19%▼ (in JPY terms)
Shin-Etsu|$37.09 (¥5,869)-1.63%▼ (in JPY terms)
Tokio Marine|$3.44 (¥544)-1.91%▼ (in JPY terms)
Fast Retailing|$476.29 (¥75,360)+2.04%▲ (in JPY terms)

JP3942400007

2026-06-24 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in Europe for combination therapy with pembrolizumab for resectable muscle-invasive bladder cancer that is unsuitable for cisplatin, providing a new treatment option as adjuvant therapy before and after surgery.”

by

2026-06-24 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received a … 続きを読む

2026-05-22 Astellas Pharma Inc. “The European CHMP has adopted a recommendation for marketing authorization of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab for cisplatin-unsuitable resectable muscle-invasive bladder cancer.”

by

2026-05-22 Astellas Pharma Inc. “The European CHMP has adopted a recommendation for marketing authorizat … 続きを読む

2026-05-14 Astellas Pharma Inc. “An application for approval in Japan has been submitted for an additional indication for the antibody-drug conjugate Padsev™ (enfortumab vedotin) in combination with pembrolizumab for the treatment of muscle-invasive bladder cancer for which cisplatin is indicated.”

by

2026-05-14 Astellas Pharma Inc. “An application for approval in Japan has been submitted for an addition … 続きを読む

2026-04-21 Astellas Pharma Inc. “The FDA has accepted an application for approval of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab, regardless of whether cisplatin is indicated, as a neoadjuvant therapy for muscle-invasive bladder cancer, and has granted it priority review.”

by

2026-04-21 Astellas Pharma Inc. “The FDA has accepted an application for approval of the antibody-drug c … 続きを読む

Contact